Thymic Epithelial Tumors: An Evolving Field.

Area of Science:

• Oncology
• Pathology
• Molecular Biology

Background:

• Thymic epithelial tumors (TETs) are rare neoplasms with diverse classifications.
• Current WHO classification divides TETs into types A, AB, B (B1-B3), and thymic carcinomas, ranging from indolent to aggressive.
• Widely accepted staging systems include TNM and Masaoka-Koga.

Purpose of the Study:

• To review the evolution of thymic epithelial tumor classification.
• To explore the molecular subgrouping of TETs and its correlation with histology.
• To discuss the impact of molecular findings on current and future therapeutic strategies.

Main Methods:

• Review of existing literature on thymic epithelial tumors.
• Analysis of histological classifications (WHO).
• Examination of molecular subgrouping and associated genetic alterations (e.g., GTF2I, HRAS, CDKN2A, TP53).

Main Results:

• TETs exhibit distinct molecular subgroups mirroring histological types: A-like, AB-like, B-like, and carcinoma-like.
• Specific mutations (GTF2I, HRAS, CDKN2A, TP53) and high tumor molecular burden characterize different subtypes.
• Molecular insights have enabled targeted therapies (tyrosine kinase inhibitors, immune-checkpoints).

Conclusions:

• Histological and molecular classifications are crucial for understanding TET heterogeneity.
• Molecular profiling is essential for developing personalized treatment approaches for TETs.
• Continued research into TETs promises further advancements in diagnosis and therapy.